Ultrasound-guided Selective Blockade of the Saphenous and Obturator Nerves Following Total Knee Arthroplasty
NCT ID: NCT02465827
Last Updated: 2015-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
75 participants
INTERVENTIONAL
2014-01-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Analgesic Effect of Combined Nerve Block and Systemic High Dose Glucocorticoid After Total Knee Arthroplasty.
NCT02374008
Genicular Nerve Block for Total Knee Arthroplasty
NCT03706313
Ultrasound-guided Blocks for Ambulatory Knee Arthroscopy
NCT01837394
Protracted Effect of Combined Nerve Blocks After Total Knee Arthroplasty
NCT02067078
USG Nerve Blocks for ACL Reconstruction
NCT01840800
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Saphenous and obturator nerve block
5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of ropivacaine 0,75% for the obturator nerve block.
Ropivacaine 0.75% for nerve blockades for both nerves mentioned.
nerve block with ropivacaine
Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with ropivacaine 0.75% for both nerve branches
Saphenous nerve block
5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.
Ropivacaine 0.75% for the saphenous nerve block and saline for the obturator nerve block
nerve block with ropivacaine and with saline
nerve blocks of the saphenous nerve with ropivacaine 0.75% and obturator nerve, posterior branch with saline
Placebo nerve block
5 ml of isotonic saline for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.
Saline for nerve blockades for both nerves mentioned.
nerve block with saline
Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with saline for both nerve branches
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
nerve block with ropivacaine
Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with ropivacaine 0.75% for both nerve branches
nerve block with ropivacaine and with saline
nerve blocks of the saphenous nerve with ropivacaine 0.75% and obturator nerve, posterior branch with saline
nerve block with saline
Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with saline for both nerve branches
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥ 18 years undergoing primary unilateral total knee arthroplasty
Exclusion Criteria
2. Inability to speak and understand Danish
3. Allergy to any drugs used in the study
4. Drug or alcohol abuse
5. Pregnancy or nursing
6. Opioid abusers
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bispebjerg Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jens Borglum Neimann
Ass professor, PhD
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BispebjergH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.